Melanoma Zelboraf

Oncology Melanoma&BRAFMutantCancerProgram
Oncology Melanoma&BRAFMutantCancerProgram AUGUST2011 t Z elb o raf™(vemurafenib/PLX4032 )—L d P gm inxk ’ sO cyF h Zelborafisanovel,oralandselectivedrugthattargetsaspecificmutationexpressedin ... Read Document

Reference ID: 3001518
Nd nd FULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE . ZELBORAF™ is indicated for the treatment of patients with unresectable or metastatic melanoma with ... Retrieve Document

Interferon - Melanoma Skin Cancer Treatment With Interferon
Learn more about interferon-alfa2b, the only approved drug for the adjuvant (post-surgery) treatment of patients with high-risk melanoma in danger of recurring (coming back). ... Read Article

Zelboraf Consumer Medicine Information - Medsafe Home Page
Consumer Medicine Information . ZELBORAF ZELBORAF is used to treat metastatic melanoma (a type of skin cancer that has spread to other parts of the body). It can only be used if your melanoma has a change (mutation) in the BRAF ... Return Document

Zelboraf™ Prescribing Information - NCCN
On behalf of Genentech, I respectfully request the NCCN Melanoma Guideline Panel to review the enclosed data for Zelboraf™ (vemurafenib) for the treatment of patients with unresectable or metastatic melanoma. Specific Changes: ... Retrieve Content

Vemurafenib (Zelboraf - Conference Management System
Vemurafenib (Zelboraf®) For the treatment of BRAF V600E mutation-positive unresectable or metastatic melanoma ... Read More

Zelboraf - European Medicines Agency
Zelboraf . vemurafenib . This is a summary of the European public assessment report (EPAR) for Zelboraf. It explains how the Zelboraf is only for patients whose melanoma tumour cells have a specific mutation called ‘BRAF V600’ in their genes. ... Retrieve Doc

First Gene-Targeted Drug For Melanoma Approved By FDA
Page 2 of 2 Zelboraf is the second melanoma drug to be approved by the FDA this year and the first therapy approved that targets a specific gene mutation. ... Return Document

Vemurafenib (Zelboraf) - Genentech
3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZELBORAF® is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF ... Fetch Content

FDA Approves Zelboraf (vemurafenib) And Companion Diagnostic ...
4/5 results, allowing doctors to know whether a person with metastatic melanoma is eligible for treatment with Zelboraf. About Zelboraf Zelboraf is an oral, small molecule, kinase inhibitor indicated for the treatment of patients with unresectable ... Retrieve Full Source

TM Covered Medication Vemurafenib (Zelboraf - HMSA
Medco Health Solutions, Inc. Zelboraf Used Under License November 2011 ZelborafTM Covered Medication Vemurafenib (ZelborafTM) What it does and how it is used ... Return Document

BRAF INHIBITORS PA SUMMARY MEDICATIONS: Mekinist, Tafinlar ...
MEDICATIONS: Mekinist, Tafinlar, Zelboraf LENGTH OF AUTHORIZATION: 1 Year For Mekinist Approvable for the diagnosis of unresectable or metastatic melanoma AND Member must have a BRAF V600E or V600K mutation as detected by an FDA-approved test, such as the THxID BRAF companion test ... Return Document

Vemurafenib Treatment For Melanoma - About.com Health
Vemurafenib (Zelboraf ®) is a medication that targets a specific mutation found in many melanomas. Vemurafenib targets the specific V600E mutation in the BRAF protein carried by 40 to 60 percent of melanomas. This medication has shown promising results as a way to halt tumor growth temporarily ... Read Article

Vemurafenib - Wikipedia, The Free Encyclopedia
Vemurafenib (INN, marketed as Zelboraf) is a B-Raf enzyme inhibitor developed by Plexxikon (now part of Daiichi-Sankyo) and Genentech for the treatment of late-stage melanoma. [1] Melanoma cells without these mutations are not inhibited by vemurafenib; ... Read Article

Zelboraf - Hidesigns.com
Step 2 (diagnosis of unresectable metastatic melanoma stage IIIC) Required quantity: 1 Look back timeframe: 365 days ICD-9 Code Description 172.9 MELANOMA OF SKIN, SITE UNSPECIFIED Texas Prior Authorization Program Clinical Edits Zelboraf ... Retrieve Doc

Zelboraf (vemurafenib) - Consumer Medicine Information CMI
ZELBORAF® pronounced (ZEL-bor-af) contains the active ingredient vemurafenib Zelboraf CMI 120426 1 of 4 PI 120426 Consumer Medicine Information ... Read Full Source

Melanoma - Wikipedia, The Free Encyclopedia
Melanoma, also known as malignant melanoma, is a type of cancer that develops from the pigment-containing cells known as melanocytes. [1] Melanomas typically occur in the skin but may rarely occur in the mouth, intestines, or eye. ... Read Article

About Skin Cancer
Last month, the FDA approved the drug Zelboraf (vemurafenib) for patients with melanoma, the deadliest form of skin cancer. The drug is designed to work only for late-stage melanoma patients whose tumors have a specific genetic defect known as the BRAF V600E mutation, which is present in ... Read Article

Zelboraf - YouTube
The new FDA Approved drug,called Zelboraf specifically designed for my type of melanoma, it kills the gene that it makesso we will see in the CT scan comi ... View Video

MediaPharm - Malignant Melanoma Therapy Gets Personal ...
The new FDA approved drug vemurafenib (Zelboraf) is offering hope for personalized treatment of one of the hardest to treat cancers. Why do I say this treatm ... View Video

ORAL DRUGS FOR METASTATIC MELANOMA
Last Revision Date: August 2014 • Is NOT covered when used in treatment of patients with wild-type BRAF melanoma. • Is NOT covered when used in combination with Zelboraf unless enrolled in a clinical ... Return Doc

Pharmacy Medical Necessity Guidelines: Zelboraf ® (vemurafenib)
3 Pharmacy Medical Necessity Guidelines: Zelboraf ® (vemurafenib) APPROVAL HISTORY November 15, 2011: Reviewed by the Pharmacy and Therapeutics Committee ... Get Content Here

ZELBORAF® (vemurafenib) Tablet
MEDICATION GUIDE ZELBORAF ® (ZEL-bor-raf) (vemurafenib) tablet What is the most important information I should know about ZELBORAF? ZELBORAF can cause serious side effects, including: ... Access Full Source

Translation Launch of the Anti-Cancer Agent / BRAF Inhibitor “Zelboraf®” - Contribution to the Treatment of Melanoma by Personalized Healthcare - ... Access Full Source

Roche Highlights Product Pipeline During Investor Event; Seven Major Read-outs From Clinical Trials Expected By The ...
Cotellic (cobimetinib) is currently under regulatory review in the U.S. and Europe for BRAF+ unresectable metastatic melanoma, in combination with Zelboraf (vemurafenib). Decisions from the FDA and EMA are expected in November and December, respectively. ... Read News